OncoMatch/Clinical Trials/NCT07103395
A Study Evaluating Neoadjuvant Chemotherapy, Concurrent Chemoradiotherapy Combined With Dual Immune Checkpoint Blockade in Patients With Locally Advanced Non-Small Cell Lung Cancer
Is NCT07103395 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Neoadjuvant therapy and Consolidative therapy for lung cancer (nsclc).
Treatment: Neoadjuvant therapy · Consolidative therapy — This study will enroll patients with locally advanced non-small cell lung cancer (NSCLC). Patients will receive neoadjuvant chemotherapy combined with dual immune checkpoint blockade (PD-1/CTLA-4), bevacizumab and thymosin alpha 1, followed by concurrent chemoradiotherapy, and finally consolidation therapy with dual immune checkpoint blockade (PD-1/CTLA-4), surufatinib and thymosin alpha 1. The study aims to evaluate the efficacy and safety of this treatment regimen.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: ALK wild-type
Required: EGFR wild-type
Required: ROS1 wild-type
Disease stage
Required: Stage III
Performance status
WHO 0–1
Prior therapy
Cannot have received: chemotherapy
No prior chemotherapy
Cannot have received: radiotherapy
No prior radiotherapy
Cannot have received: surgery
No prior surgery
Cannot have received: targeted therapy
No prior targeted therapy
Cannot have received: immunotherapy
No prior immunotherapy
Cannot have received: anti-PD-1 therapy
Prior use of anti-PD-1, anti-PD-L1, or anti-CTLA4 antibodies
Lab requirements
Blood counts
absolute neutrophil count ≥ 1.5 × 10⁹/l; platelets ≥ 100 × 10⁹/l; hemoglobin ≥ 9.0 g/dl
Kidney function
creatinine clearance ≥ 50 ml/min as calculated by the cockcroft-gault formula
Liver function
serum bilirubin ≤ 1.5 × upper limit of normal (uln); ast and alt ≤ 2.5 × uln
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify